Protein Kinases in Drug Discovery: Volume 124

Informationen zum Autor Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.

Autorentext
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.

Inhalt

1. Transporter proteins and its implication in human diseases
   Ritika Kabra and Shailza Singh
2. Protein kinase CK2 inhibition as a pharmacological strategy
   Christian Borgo and Maria Ruzzene
3. Emerging role of protein kinases in diabetes mellitus: From mechanism to therapy
   Preeti Gupta, Aaliya Taiyab, and Md Imtaiyaz Hassan
4. Dual roles of ATP-binding site in protein kinases: Orthosteric inhibition and allosteric regulation
   Mingyu Li, Ashfaq Ur Rehman, Yaqin Liu, Kai Chen, and Shaoyong Lu
5. Pseudokinases: Prospects for expanding the therapeutic targets armamentarium
   Nayana Devang, Adyashree Pani, and G.K. Rajanikant
6. Chemogenomics and bioinformatics approaches for prioritizing kinases as drug targets for neglected tropical diseases
   Joyce Villa Verde Bastos Borba, Arthur Carvalho Silva, Marilia Nunes Nascimento Lima, Sabrina Silva Mendonca, Nicholas Furnham, Fabio Trindade Maranhão Costa, and Carolina Horta Andrade
7. Targeting malaria protein kinases
   G.C. Cassiano, T.A. Tavella, M.N. Nascimento, D.A. Rodrigues, P.V.L. Cravo, Carolina Horta Andrade, and Fabio Trindade Maranhão Costa
8. Yeast-based high-throughput screens for discovery of kinase inhibitors for neglected diseases
   T.A. Tavella, G.C. Cassiano, Fabio Trindade Maranhão Costa, P. Sunnerhagen, and E. Bilsland
9. Structural studies of full-length receptor tyrosine kinases and their implications for drug design
   Adam Bajinting and Ho Leung Ng